Data Sheet 1_ELDA: real-time functional drug profiling in acute lymphoblastic leukemia.pdf

IntroductionPediatric acute lymphoblastic leukemia (ALL) has cure rates exceeding 80%, yet approximately 20% of patients experience relapse, for whom treatment remains challenging. The biological and clinical heterogeneity of ALL complicates therapeutic decision-making, especially in relapse. A functional, patient-specific tool to identify effective drugs could complement current stratification approaches and potentially optimize therapy selection.
MethodsWe developed ELDA (Ex vivo Leukemia Drug Advisor), a novel drug screening platform based on time-lapse bright-field microscopy. Primary ALL cells were co-cultured with human bone marrow stromal cells in a three-dimensional collagen matrix, replicating a physiologically relevant microenvironment. Candidate drugs were added, and wells were imaged every 30 min for 96 h. A custom image analysis algorithm quantified viable cells by detecting subtle cell membrane movements, enabling real-time monitoring of treatment response.
Results and discussionELDA’s results demonstrated strong concordance with established cytotoxicity assays, including MTT and Calcein-AM, validating its performance in vitro. Drug profiling of 25 pediatric ALL samples against a panel of 50 clinically relevant and experimental agents revealed distinct sensitivity and resistance patterns for each patient. Notably, heterogeneity was observed even among cases sharing the same genetic alterations, underscoring the limitations of genotype-based therapeutic predictions alone. Drugs with similar mechanisms of action exhibited correlated activity profiles, confirming the biological consistency of the assay. Importantly, ELDA-predicted differences in sensitivity to dexamethasone and vincristine were validated in vivo, further supporting its translational relevance. ELDA is a standardized and validated ex vivo drug screening methodology capable of generating individualized drug response profiles for pediatric ALL. Beyond its investigational potential in precision oncology, ELDA offers a platform for preclinical evaluation of novel agents and drug combinations.